Bd

•Als ODP, PDF herunterladen•

0 gefällt mir•389 views

Phrixos

jeu cyber francas

Weitere ähnliche Inhalte

Andere mochten auch

Stages of Prostate Cancer

New Jersey CyberKnife

Molecular imaging and therapy in prostate cancer

Molecular Imaging Society of India (MISI)

Molecular Imaging

Chaz874

In this presentation, Dr. Kwon speaks about a novel method to assess patients who are experiencing a rise in PSA after treatment for prostate cancer. Specifically, he will discuss the utility of C11-choline PET scanning as an emerging technology to determine sites of prostate cancer relapse after initial treatment failure. This will include discussions of identifying sites of local as well as systemic cancer recurrence following initial surgical, radiation, hormonal as well as chemotherapeutic treatment. Dr. Kwon’s presentation will also elucidate how proper identification of sites of prostate cancer recurrence using C11-choline PET plays and instrumental role in determining subsequent steps for optimal therapy including single or multimodality treatment.

DrKwon NewImaging C11CholinePET

PCRI_2012conf

Advantages of Ga-68 4D PET/CT Ventilation Perfusion (V/Q) Imaging

drhofman

Ca prostate [edmond]

Edmond Wong

Stages of Prostate Cancer

San Diego Radiosurgery

The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, being African-American, and some genetic changes. Symptoms of prostate cancer may include: -- Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling -- Low back pain -- Pain with ejaculation Your doctor will diagnose prostate cancer by feeling the prostate through the wall of the rectum or doing a blood test for prostate-specific antigen (PSA). Other tests include ultrasound, x-rays, or a biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments.

Prostate Cancer

fitango

Amol april prostate cancer imaging

Amol Gulhane

Image registration and data fusion techniques.pptx latest save

M'dee Phechudi

Gleason system of grading prostate cancer

Gideon Mutai

своевременная диагностика и терапия данного заболевания до сих пор являются нерешенной клинической задачей. По данным на 2011 г., заболе- ваемость раком простаты в России составила 10,7% (40 тыс. первичных случаев) мужского населения, причем в 60% случаев заболевание диа- гностировали на поздней (III–IV) стадии, когда неизбежен процесс активного роста и распространения метастазов. Методы анатомической визуализации при диагностике данного заболевания имеют низкую чувствительность и специфичность. Методы метаболической визуализации, использующие в качестве маркера простатспецифический антиген (ПСА), также малоэффективны. В качестве маркера для диагностики и лечения метастатического рака простаты предлагается рассматривать простатспецифический мембранный антиген (ПСМА). За рубежом проходят клинические испытания наиболее перспективные диагностические радиофармпрепараты на основе малых пептидных молекул, моди- фицированных мочевиной, которые отличаются наибольшим сродством к ПСМА. Отличительной особенностью этих соединений является их благоприятная фармакокинетика, высокое и длительное накопление в опухоли и метастазах, быстрое выведение из организма. Ключевые слова: метастатический рак предстательной железы, простатспецифический мембранный антиген, радиофармпрепараты. (Для цитирования: Власова О.П., Герман К.Э., Крылов В.В., Петриев В.М., Эпштейн Н.Б. Новые радиофармпрепараты для диагности- ки и терапии метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник РАМН. 2015; 70 (3): 360–365. Doi: 10.15690/vramn.v70i3.1334)

German pres2-prostate membrane antigen

Konstantin German

Prostate cancer update

Ahmed Tawfeek

Management of prostate cancer

damuluri ramu

Psa

janmacmann

Poster Presentation Title: A Phase 1 clinical trial of a therapeutic prostate cancer vaccine containing PSA/IL-2/GM-CSF in PSA defined biochemical recurrent prostate cancer patients Meeting: CRI-CIMT-EATI-AACR: Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival Immunotherapy for cancer has had two main approaches that have lead to clinical applications. The first is stimulating immune responses to tumor cells with cytokines or cellular immunotherapy and the second is blocking tumor immune evasion and the associated inhibition of T-cell activation with antibodies to the CTLA-4 receptor, PD-1 receptor or PD-L1. At OncBioMune, we have taken a different approach and have developed therapeutic cancer vaccines that are a combination of tumor antigens (whole cells or proteins) with biological adjuvants (the cytokines IL-2 and GM-CSF). This study is a Phase 1a/1b clinical trial of a PSA/IL-2/GM-CSF vaccine in recurrent prostate cancer in hormone-naïve and hormone-independent patients. Major inclusion criteria include adenocarcinoma of the prostate, rising serum PSA and no measurable disease. Phase 1a examines the rate of dose limiting adverse events (DLAEs) in an initial course of 6 vaccinations (“induction vaccination”). The Phase 1b examines the rate of DLAEs with a continued coarse of an additional 6 vaccinations (“maintenance vaccine”). All patients will receive intradermal injections of the PSA/IL-2/GM-CSF vaccine at weeks 1, 2, 3, 7, 11, and 15. In an additional 28 patients the six maintenance vaccines will alternate IL-2 and the complete vaccine (PSA/IL-2/GM-CSF) at weeks 23, 27, 31, 35, 39 and 43. To date, twelve of twenty patients in the Phase 1a portion of the trial have received at least one vaccine injection and ten patients have received all 6 vaccines. Seven of the ten patients that have received 3 vaccines had increased responses to PSA in a lymphocyte blastogenesis assay and five of the nine patients had an increase in their response after 6 vaccines. None of the patients vaccinated in the Phase 1a portion have had a DLAE and enrollment continues in the Phase 1a.

OncBioMune Presentation Phase 1 Prostate Cancer Trial

OncBioMune Pharmaceuticals, Inc.

Introduction of the mechatronic device creation specialist GBN Systems GmbH from the greater Bavarian Munich area. The team around CEO Siegfried Foerg, head of engineering Max Bichlmaier and head of business development Harry Flint offers complex solutions for demanding customers in the fields of: - Medical Technology (nulear medicine, lab tech, biotech, healthcare) - Semiconductor Industry (Chiptester, Die Bonder, Speedtester) - Additive Manufacturing (3D Printer, 3D Scanning, 3D Detection) - Special Series From Development over prototype to small series production. A presentation of (c) Harry Flint in charge of: GBN Systems GmbH Fellnerstr. 2 D-85656 Buch am Buchrain Germany Contact: harry.flint@gbn-systems.com http:www.gb-systems.com

EN-16S. GBN Systems - Performing Mechatronics - Made in Bavaria

Harry Flint

BPH, Prostate Cancer, Testicular Cancer

Patrick Carter

Andere mochten auch (18)

Stages of Prostate Cancer

Molecular imaging and therapy in prostate cancer

Molecular Imaging

DrKwon NewImaging C11CholinePET

Advantages of Ga-68 4D PET/CT Ventilation Perfusion (V/Q) Imaging

Ca prostate [edmond]

Stages of Prostate Cancer

Prostate Cancer

Amol april prostate cancer imaging

Image registration and data fusion techniques.pptx latest save

Gleason system of grading prostate cancer

German pres2-prostate membrane antigen

Prostate cancer update

Management of prostate cancer

Psa

OncBioMune Presentation Phase 1 Prostate Cancer Trial

EN-16S. GBN Systems - Performing Mechatronics - Made in Bavaria

BPH, Prostate Cancer, Testicular Cancer

Bd

1. Complètement *** ! A vous de deviner !!

2. Pendant le travail ...

3. Un comportement inhabituel ...

4. Usain Bolt n'as qu'a bien se tenir !

5. C'est quoi ça ?

6. C'est quoi ça ?

Bd

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Andere mochten auch

Andere mochten auch (18)

Bd